Edition:
India

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

5.23USD
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
$5.23
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,897
52-wk High
$10.90
52-wk Low
$4.42

Latest Key Developments (Source: Significant Developments)

Therapix Biosciences Q3 loss per share $0.30
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Therapix Biosciences Ltd : :Therapix Biosciences reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.30.Therapix Biosciences Ltd - ‍cash totaled $10.7 Million as of September 30, 2017, compared to $11.8 million as of June 30, 2017​.  Full Article

Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Therapix Biosciences Ltd :Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea.  Full Article

Therapix biosciences says CEO Dr. Haber resigned
Thursday, 25 May 2017 

May 24 (Reuters) - Therapix Biosciences Ltd :Therapix biosciences announces ceo change.Says ceo dr haber resigned.Therapix biosciences ltd - board of directors is undertaking a search to identify a permanent, u.s. Based chief executive officer.  Full Article

Therapix Biosciences files application with FDA for an Orphan designation for Tourette's Syndrome drug
Wednesday, 15 Jun 2016 

: Therapix biosciences ltd says estimates that an initial clinical trial will begin in h2/2016 .Therapix biosciences filed an application with the fda to approve an "orphan" designation for the drug developed based on the entourage technology for treating tourette's syndrome.  Full Article

BRIEF-Therapix Biosciences plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids

* Therapix Biosciences Ltd plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids Source text for Eikon: Further company coverage: